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Different Expression and Function of the Endocannabinoid System in Human Epicardial Adipose Tissue in 
Relation to Heart Disease 
Giuseppe Cappellano, Francesca Uberti, Philippe Primo Caimmi, Stefano Pietronave, David A.S.G. Mary, 
Chiara Dianzani, Ezio Micalizzi, Matteo Melensi, Renzo Boldorini, Gabriella Nicosia, Enrico Crosio, Annalisa 
Chiocchetti, Franco Aina, Maria Prat, Umberto Dianzani, Giovanni Vacca, Cristiano Ariatti, Elena Grossini 
Abstract 
Background 
The endocannabinoid system reportedly plays a role in the pathogenesis of cardiovascular diseases. This 
system is expressed also in adipose tissue, which could thus be involved in cardiac disorders through 
modulation of metabolically triggered inflammation. The current study aims to determine the relevance of 
the endocannabinoid system in epicardial adipose tissue in heart disease. 
Methods 
Expression of the endocannabinoid receptors CB1 and CB2, and of the endocannabinoid-degrading enzyme, 
fatty acid amidohydrolase, and activation of protein kinase A (PKA), phospholipase C (PLC), protein kinase C 
(PKC), endothelial nitric oxide synthase (eNOS) and inducible (i)NOS, and extracellular signal-regulated 
kinases 1 and 2 (ERK1/2) (a member of the reperfusion-injury salvage kinase pathway), were analyzed by 
Western blot in patients after coronary artery bypass surgery (ischemics; N = 18) or valve surgery 
(nonischemics; N = 15) and in preadipocytes isolated from epicardial adipose tissue. 
Results 
In ischemics, the CB1-to-CB2 expression ratio shifted toward CB1 and was accompanied by higher PKA 
activation. In contrast, in nonischemics, CB2, fatty acid amidohydrolase, PLC and PKC, and ERK1/2 were 
upregulated. Moreover, NO production and iNOS-to-eNOS ratios were higher in preadipocytes from 
ischemics. 
Conclusions 
These results show a different modulation and functioning of the endocannabinoid system in ischemics 
compared with nonischemics. Hence, while CB2, PLC and PKC, ERK1/2, and eNOS are more strongly 
expressed in patients without ischemic heart disease, high CB1 and PKA expression is associated with low 
survival intracellular pathway activation and high iNOS activation in ischemic heart disease patients. The 
changes in the endocannabinoid system in ischemics may contribute to cardiac dysfunction and therefore 
represents a potential therapeutic target. 
Résumé 
Introduction 
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Le système endocannabinoïde jouerait un rôle dans la pathogenèse des maladies cardiovasculaires. Ce 
système est aussi exprimé dans le tissu adipeux, qui pourrait par conséquent être impliqué dans les 
troubles cardiaques par la modulation de l'inflammation métaboliquement déclenchée. L'étude actuelle a 
pour but de déterminer la pertinence du système endocannabinoïde dans le tissu adipeux épicardique de la 
maladie du cœur. 
Méthodes 
L'expression des récepteurs CB1 et CB2 des endocannabinoïdes, et de l'enzyme responsable de la 
dégradation de l'endocannabinoïde, l'amidohydrolase des acides gras et l'activation de la protéine kinase A 
(PKA), la phospholipase C (PLC), la protéine kinase C (PKC), la synthase endothéliale de l'oxyde nitrique 
(eNOS) et (i)NOS inductibles et des kinases 1 et 2 régulées par les signaux extracellulaires (ERK1/2) (un 
élément de la voie RISK [reperfusion-injury salvage kinase]) ont été analysés chez les patients par leWestern 
Blot après le pontage coronarien (ischémiques; N = 18) ou la chirurgie valvulaire (non ischémiques; N = 15), 
et dans les préadipocytes isolés du tissu adipeux épicardique. 
Résultats 
Chez les ischémiques, le ratio d'expression CB1 : CB2 s'est déplacé vers CB1 et a été accompagné d'une 
activation élevée de la PKA. En revanche, chez les non ischémiques, le CB2, l'amidohydrolase des acides 
gras, le PLC et PKC et l'ERK1/2 ont été régulés à la hausse. De plus, la production de NO et les ratios iNOS : 
eNOS ont été élevés dans les préadipocytes des patients ischémiques. 
Conclusions 
Ces résultats montrent une modulation et un fonctionnement du système endocannabinoïde différents 
chez les ischémiques comparativement aux non ischémiques. En conséquence, bien que le CB2, le PLC et 
PKC, le ERK1/2 et la eNOS sont exprimés de manière plus importante chez les patients sans maladie 
cardiaque ischémique, l'expression élevée de CB1 et de PKA est associée à une faible activation des voies 
de signalisation intracellulaire de survie et une activation élevée de la iNOS chez les patients ayant une 
maladie cardiaque ischémique. Les changements dans le système endocannabinoïde chez les ischémiques 
peuvent contribuer au dysfonctionnement cardiaque, représentant ainsi une cible thérapeutique 
potentielle. 
The endocannabinoid system (ECS) comprises 2 types of G-protein-coupled cannabinoid (CB) receptors, 
CB1 and CB2, and their endogenous ligands, the endocannabinoid arachidonylethanolamide (anandamide) 
and 2-arachidonoyl-glycerol (2-AG), which are degraded by fatty acid amidohydrolase (FAAH) and monoacyl 
glycerol lipase.1 
CB1 and CB2 belong to the 7-transmembrane G-protein-coupled receptor family and share 68% homology 
within the transmembrane domains and 44% homology throughout the total protein. The main signal 
transduction includes cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA), p38-mitogen-
activated protein kinase (MAPK), extracellular signal-regulated kinases 1 and 2 (ERK1/2) and phospholipase 
C (PLC) and protein kinase C (PKC).2 CB receptors are expressed in many tissues3 and are involved in several 
physiological and pathologic processes.4, 5 and 6 In the cardiovascular system, CB1 and CB2 are expressed in 
the atria, ventricles, cardiomyocytes, and vascular endothelial cells,7, 8 and 9 and have been implicated in 
cardiometabolic regulation and vasodilatation.10 Furthermore, they were reported to play a role in 
metabolically triggered inflammation, or “metaflammation,” and vascular muscle cell proliferation involved 
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in cardiovascular diseases, as well as in metabolic disorders.11, 12 and 13 In particular, CB1 stimulation may 
support progression of metaflammation and cardiac dysfunction,11 and CB2 stimulation may protect against 
cardiac ischemia and reperfusion injuries7 through a PKC, p38-MAPK, and ERK1/2–mediated signalling 
pathway.14 Moreover, various endocannabinoid agonists were shown to protect cardiac cells against 
ischemia and reperfusion injury or hypoxia through modulation of inducible nitric oxide synthase (iNOS) 
and endothelial nitric oxide synthase (eNOS) cardiac equilibrium and nitric oxide (NO) production.9 and 15 
Epicardial adipose tissue (EAT), which substantially increases with obesity, may play a key role in cardiac 
disease.16 Hence, EAT is a metabolically active organ and a source of several bioactive molecules that might 
substantially affect the myocardium and coronary arteries.16, 17, 18 and 19 Its proximity to the myocardial 
tissue suggests that factors released by EAT may affect coronary wall inflammation, cardiac function, and 
progression of atherosclerosis.14 and 20 Since adipocytes and preadipocytes are endowed with the full 
biochemical machinery to synthesize, degrade, and respond to endocannabinoids, our study analyzed the 
ECS in EAT from cardiac patients with and without ischemic heart disease in order to assess its involvement 
in cardiac diseases. 
Methods 
Patients 
Patients were recruited at the Cardiac Surgery Unit, Azienda Ospedaliero-Universitaria Maggiore della 
Carità di Novara. They underwent either coronary artery bypass graft (N = 18) or valve replacement or 
repair (N = 15). Nonischemic patients showed no angiographic evidence of coronary disease. In each 
patient, 2 or 3 biopsies of EAT, close to the proximal portion of the right coronary artery, were taken 
immediately before the onset of extracorporeal circulation. Thoracic biopsies of subcutaneous adipose 
tissue (SAT) were taken as controls. Tissue specimens were flash frozen immediately for reverse 
transcription–polymerase chain reaction (RT-PCR) and Western blot analysis or immediately processed to 
prepare preadipocytes. All patients provided written informed consent. The study complied with the 
Declaration of Helsinki for investigation in human beings and was approved by the local ethical committee. 
Isolation of preadipocytes 
Samples were placed in a saline solution and processed as previously described.21Tissue was cut into about 
1 cm2 sections and digested with type I collagenase (1 g/mL; Invitrogen Life Technologies, Carlsbad, CA) in 
Hanks balanced salt solution (Sigma, Milan, Italy) plus 1% penicillin-streptomycin (Euroclone, Pero, Milan, 
Italy) for 1 hour at 37°C. Samples were then filtered with sterile gauze and centrifuged at 190g for 10 
minutes. The pellet containing preadipocytes was plated in a 1:1 mix of Dulbecco's Modified Eagle F12 
medium supplemented with 10% fetal calf serum (Euroclone), 100 IU/mL penicillin, 100 μg/mL 
streptomycin, and glutamine, and incubated at 37°C in the presence of 5% CO2. Cells were used between 
the third and sixth passage. 
Western blot analyses 
Tissue samples and preadipocyte s preparations were processed for sodium dodecyl sulfate polyacrylamide 
gel electrophoresis as described in the Supplementary Material. Lysates were probed with antibodies 
directed against p-p44/42 MAPK (Thr202/Tyr204), p-eNOS (Ser1177), eNOS (Cell Signaling Technology Inc, 
Denver, CO), iNOS (Abcam, Cambridge, UK), p-PKA, p-PLC-γ, CB1, CB2, FAAH (Santa-Cruz, Tebu-Bio, Milan, 
Italy), and p-PKC (Abfrontier, Digital Valley, Seoul, South Korea). 
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Griess assay 
NO production was measured by the Griess assay (Promega, Madison, WI), as previously 
described.22 Preadipocytes (1 × 104) were incubated in 24-well plates for 4 hours in Dulbecco's Modified 
Eagle's Medium without red phenol (Euroclone) and stimulated with the CB receptor agonists 2-AG 
(Cayman, Ann Arbor, MI), JWH015 (Sigma), or methanandamide (Cayman) for 60 seconds, 180 seconds, and 
300 seconds. In a series of experiments, cells were pretreated for 30 minutes with the CB receptor 
antagonists AM630 (Cayman) or AM251 (Cayman), the cAMP-dependent PKA inhibitor H89 (Sigma), or the 
PKC blocker calphostin C (Tocris Biosciences, Ellisville, MO), before adding CB receptor agonists. Treatment 
with tumour necrosis factor α (Sigma) was used as positive control. Culture supernatants were then mixed 
with equal volumes of the Griess reagent and incubated in the dark at room temperature for 10 minutes; 
absorbance was measured by a spectrometer at 570 nm. NO production corresponded to the NO (μmol) 
produced after each stimulation by samples, each containing 1.5 μg of protein. 
In another series of experiments, the diaminofluorescein fluorophore system (DAF-FM; Molecular Probes, 
Invitrogen, Carlsbad, CA) was used (see Supplementary Material). 
RT-PCR 
Tissue samples were treated with TRIzol reagent (Invitrogen, San Diego, CA) to extract RNA, and 0.5 μg total 
RNA was then reverse transcribed into complementary DNA with the ThermoScript RT-PCR System 
(Invitrogen) and Taq polymerase (Invitrogen) in a 25 μL final volume with primers: CB1: 5-
GAGCTCAGCCTAATCAAAG-3 (forward), 5′-TATGTACCTGTCGATGGC-3′ (reverse); CB2: 5′-
ACAAGCTCAGTGGAATCTG-3′ (forward), 5′-ATAGTCACGCTGCCAATC-3′ (reverse); and GA6DH: 5′-
ACCACAGTCCATGCCATC-3′ (forward), 5′-TCCACCACCCTGTTGCTGTA-3′ (reverse). Semiquantitative analysis 
was done through automated densitometry (VersaDoc; Bio-Rad Laboratories Ltd, Hercules, CA) in a double-
blind manner. 
Statistical analysis 
The STATVIEW version 5.0.1 for Microsoft Windows (SAS Institute Inc, Cary, NC) provided statistical 
analysis. Continuous and categorical variables were respectively expressed as mean ± SD and percentages. 
Two-way ANOVA followed by the Bonferroni post hoc test and the Mann-Whitney test were used to 
examine changes in NO production, protein phosphorylation, and messenger RNA levels. The chi-square or 
Fisher exact test was used to compare categorical variables. Statistical significance was set at P < 0.05. 
Results 
As reported in Table 1, ischemic and nonischemic patients differed only in left ventricular ejection fraction 
and acetylsalicylic acid intake. 
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Table 1. 
Demographic data 
 
 
Ischemic patients (n = 
18) 
Nonischemic patients (n = 
15) P 
Men-to-women (n) 15:3 12:3 > 0.05 
Age (years) 66.1 ± 9 67.6 ± 8.2 > 0.05 
Weight (kg) 76.1 ± 10 78.3 ± 18.6 > 0.05 
BMI (Kg/m2) 27.6 ± 3.8 27.2 ± 5 > 0.05 
Dyslipidemia (n) 12 9 > 0.05 
Hypertension (n) 15 13 > 0.05 
Diabetes (n) 12 8 > 0.05 
Previous myocardial infarction 11 0 < 0.001 
History of heart failure 13 1 < 0.001 
Left ventricular ejection fraction 
(mL) 
48.6 ± 9.9 58.1 ± 7.4 0.008 
Current smoker (n) 3 2 > 0.05 
Former smoker (n) 9 8 > 0.05 
β-blocker (n) 8 6 > 0.05 
ACEI (n) 5 3 > 0.05 
Sartans (n) 5 3 > 0.05 
Nitrates (n) 8 4 > 0.05 
Furosemide (n) 6 5 > 0.05 
ASA (n) 13 3 0.003 
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Ischemic patients (n = 
18) 
Nonischemic patients (n = 
15) P 
Statins (n) 6 5 > 0.05 
Insulin (n) 3 3 > 0.05 
Oral hypoglycemic agents (n) 6 3 > 0.05 
No. vessels revascularized:    
 1 (n) 2   
 2 (n) 4   
 3 (n) 7   
 4 (n) 5   
Mean 2.8 ± 0.9   
Mitral valve surgery (n)  7  
 Stenosis  3  
 Regurgitation  3  
 Mixed  1  
Aortic valve surgery (n)  8  
 Stenosis  4  
 Regurgitation  3  
 Mixed  1  
ACEI, angiotensin-converting enzyme inhibitors; ASA, acetylsalicylic acid; BMI, body mass index; Sartans, AT1-receptor antagonists. 
 
Western blot showed that CB1 expression was higher in ischemics than in nonischemics, whereas CB2 and 
FAAH expression were higher in nonischemics (Fig. 1, A and B). Semiquantitative RT-PCR confirmed 
different CB1 expression, whereas CB2 showed no differences (Fig. 1, C and D). Moreover, activated PKA 
and iNOS levels were higher in ischemics than in nonischemics, whereas PLC, PKC, and ERK1/2 levels were 
higher in nonischemics than in ischemics (Fig. 2). 
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Figure 1.  
 
 8 
Expression of endocannabinoid system in epicardial adipose tissue (EAT). (A) Example of Western blot performed from EAT from 4 
ischemic (I) and 4 nonischemic (V) patients and from subcutaneous adipose tissue (SAT) of 1 ischemic patient (SI) and 1 
nonischemic patient (SV). (B) Densitometric analysis for CB1 or CB2 receptors and FAAH on lysates from epicardial and SAT from 
ischemic (N = 18) and nonischemic (N = 15) patients. U937 = macrophage-like cells (negative control for CB1). a:P < 0.05 vs V, I, SV, 
and SI.(C, D) RT-PCR and densitometric analysis of messenger RNA for CB1 and CB2 receptor expression in EAT from ischemic (n = 4) 
and nonischemic (n = 4) patients. Samples included SAT in ischemic and nonischemic patients and negative control (Co), as well. 
Reported data are mean ± SD. FAAH, fatty acid amidohydrolase; RT-PCR, reverse transcription–polymerase chain reaction. 
 
 
Figure 2.  
 
 9 
Expression of activated PKA, ERK1/2, PLC, PKC, iNOS, and eNOS in epicardial adipose tissue (EAT). Densitometric analysis of 
Western blot performed in EAT and subcutaneous adipose tissue (SAT) obtained from 18 ischemic patients and 15 nonischemic 
patients. Only EAT shows a different activation of the PKA, ERK1/2, PLC/PKC, eNOS, and iNOS. Reported data are mean ± SD. The 
assay was repeated twice. ERK1/2, extracellular signal-regulated kinases 1 and 2; eNOS, endothelial nitric oxide synthase; I, EAT 
from ischemic patients; iNOS, inducible nitric oxide synthase; PLC, phospholipase C; PKA, protein kinase A; PKC protein kinase C; SI, 
SAT from ischemic patient; SV, SAT from nonischemic patients; V, EAT from nonischemic patients. 
Western blot analysis in preadipocytes confirmed the different CB receptor subtype expression in ischemics 
and nonischemics (Fig. 3). As shown in Figure 3, increasing concentrations of the CB1 agonist 
methanandamide (0.001 μM-100 μM) and of the CB1/CB2 agonist 2-AG (0.001 μM-100 μM) induced higher 
NO release in ischemics than in nonischemics (P < 0.05). In contrast, the CB2 agonist JWH015 (0.001 μM-
100 μM) was more effective in nonischemics. Tumour necrosis factor α induced a high increase in NO 
production, similar to that elicited by methanandamide in ischemics ( Fig. 4). Results obtained with the 
diaminofluorescein fluorophore method confirmed those obtained with the Griess assay (Supplemental Fig. 
S1). 
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Figure 3.  
CB agonists induce a dose-response and time-course production of nitric oxide (NO) in preadipocytes. NO production (%) was 
measured by Griess assay during preadipocyte stimulation with 2-arachidonoyl-glycerol (2-AG), methanandamide (MET), and 
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JWH015. Reported data are mean ± SD of 5 independent experiments for each experimental protocol. Western blot performed in 
preadipocytes shows different CB expression in nonischemic and ischemic patients 
 
Figure 4.  
Modulation of cannabinoid (CB)-mediated nitric oxide (NO) production by different agents in preadipocytes. (A, B) Effects of CB1 
and CB2 receptor agonists on NO production measured through Griess assay in the absence or presence of CB receptors 
antagonists; 2-arachidonoyl-glycerol (2-AG), methanandamide (MET), JWH, and tumour necrosis factor α were administrated for 60 
seconds. AM630 = CB2 receptor blocker; AM251= CB1 receptor blocker; C = control; JWH= JWH015. (A) a, b, c, d, h:P <0.05 vs 
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control; b, c, e, h:P < 0.05 vs a; c, g, h:P < 0.05 vs b; f, h:P < 0.05 vs c. (B) a, b, c, e, h:P < 0.05 vs control; b, c, f, h:P < 0.05 vs a; c, g:P 
< 0.05 vs b; h:P < 0.05 vs c. (C, D) Effects of CB1 and CB2 receptor agonists on NO production in the absence or presence of PKA and 
PKC blockers; 2AG, MET, and JWH were administrated for 60 seconds; a, b, c:P < 0.05 vs control; b, c, d:P < 0.05 vs a; c, e:P < 0.05 
vsb; f:P < 0.05 vs c. Reported data are mean ± SD of 5 independent experiments for each experimental protocol. PKA, protein 
kinase A; PKC, protein kinase C; H89, PKA inhibitor; CALP, calphostin C, PKC inhibitor. 
Cell response specificity to CB1 and CB2 receptor agonists was examined by performing the above cell-
stimulation experiments with 2-AG, methanandamide, and JWH015 (60 seconds and 300 seconds) in the 
absence or presence of the CB1 or CB2 antagonist (AM251 and AM630, respectively; 10 μM). In ischemics, 
AM251 noticeably inhibited the response to methanandamide and to 2-AG but not to JWH015, whereas 
AM630 decreased the response only to JWH015. In nonischemics, AM251 inhibited the response to 
methanandamide but had no significant effect on response to 2-AG and JWH015, whereas AM630 inhibited 
the response to JWH015 and 2-AG, but not to methanandamide (Fig. 4 and Supplemental Fig. S2). 
Moreover, as shown in Figure 4 and Supplemental Figure S2, H89 (1 μM) abolished the response to 
methanandamide and significantly reduced the response to 2-AG and JWH015 in ischemics only. By 
contrast, calphostin C (1 μM) abolished the effect of JWH015 and 2-AG and significantly reduced that of 
methanandamide in nonischemics only. 
Last, Western blot showed that 2-AG and methanandamide activated PKA (Fig. 5) and iNOS (Fig. 6) at higher 
levels in cells from ischemics than in those from nonischemics. In contrast, JWH015 activated PLC, PKC (Fig. 
5), eNOS, and ERK1/2 (Fig. 6) at higher levels in cells from nonischemics than in cells from ischemics. These 
data confirmed those obtained in whole EAT, indicating predominant involvement of CB1 in ischemics and 
CB2 in nonischemics. 
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Figure 5.  
CB agonists differentially activate PKA, PLC and PKC in preadipocytes. (A, B, C) Western blot and densitometric analysis of p-PKA, p-
PLC, and p-PKC are reported. As shown, a different activation of p-PKA and p-PLC/p-PKC in response to CB agonists was found 
between ischemics and nonischemics. The abbreviations are the same used in previous Figures. Reported data are mean ± SD of 5 
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independent experiments for each experimental protocol. 2-AG, 2 arachidonoyl-glycerol; C, control; I, ischemic patient; JWH, 
JWH015; MET, methanandamide; PLC, phospholipase C; PKA, protein kinase A; PKC protein kinase C; V, nonischemic patient. 
 
Figure 6.  
 
 15 
CB agonists differentially activate eNOS, iNOS, and ERK1/2 in preadipocytes. (A, B, C) Western blot and densitometric analysis of p-
eNOS, iNOS, and ERK1/2 are reported. CB agonists caused higher iNOS activation in preadipocytes from ischemics, whereas the 
activation of eNOS and ERK1/2 was higher in those from nonischemics. Reported data are mean ± SD of 5 independent experiments 
for each experimental protocol. C, control; ERK1/2, extracellular signal-regulated kinases 1 and 2; eNOS, endothelial nitric oxide 
synthase; I, ischemic patient; iNOS, inducible nitric oxide synthase; JWH, JWH015; MET, methanandamide; V, nonischemic patient. 
Discussion 
This study showed different CB1 and CB2 expression and function in EAT between ischemics and 
nonischemics and suggests that these differences may play a role in the cardiac dysfunction developed by 
the former. 
ECS expression and function in cardiovascular pathology 
The ECS is reportedly involved in the physiological regulation of food intake and metabolism of energetic 
substances23 and in the regulation of the cardiovascular system. Tonic activation of CB1 is implicated in the 
development of various cardiovascular risk factors in obesity, metabolic syndrome, and diabetes,24 and 
furthermore, CB1 antagonists improve survival in rat models of myocardial ischemia25and cardiac function 
in cardiomyopathy.26 Likewise, the protective effect of endocannabinoids via CB2 has been demonstrated 
in rat models of acute and chronic myocardial ischemia.15 CB2 activation can limit the endothelial 
inflammatory response, chemotaxis, and inflammatory cell adhesion and activation in atherosclerosis and 
reperfusion injury.24 Moreover, increasing evidence implicates the ECS in the pathogenesis of various 
cardiovascular diseases27 and in the cardiovascular risk factors associated with obesity, metabolic 
syndrome, and diabetes.13, 27, 28 and 29 Hence, pathologic overactivation of the ECS in various forms of 
shock and heart failure can contribute to the cardiodepressive state by activation of CB1 receptors.24 
Shift of CB1-to-CB2 ratio and FAAH expression in EAT in ischemics and nonischemics 
The results obtained in the present study confirm these reports. Hence, comparison of EAT from ischemics 
and nonischemics showed a shift of the CB1-to-CB2 expression ratio detected through Western blot toward 
CB1 in the former, accompanied by downregulation of FAAH, which is expected to support the 
endocannabinoid function. It is interesting that the semiquantitative analysis of messenger RNA of CB1 also 
confirmed the above findings. Moreover, the different expressions were detected in EAT but not in SAT, 
which suggests that the direct interaction between EAT and myocardial tissue may influence the ECS in EAT, 
and the EAT profile may affect myocardium. 
A dichotomous role has been attributed to EAT. Under physiological conditions, EAT could have a protective 
effect on coronary arteries and cardiac function, whereas possible hemodynamic abnormalities could turn 
it into an adverse proinflammatory organ. Additionally, since EAT and myocardial tissues share the same 
coronary arterial supply, it is reasonable to hypothesize that changes in local vascularization may influence 
the effects of EAT on cardiac functionality30 also through a modulation of the biochemical and metabolic 
pattern and receptor expression involving the ECS. 
Changes in NO release and related signalling examined in preadypocytes isolated from EAT taken from 
ischemics and nonischemics 
We found that treatment of EAT-derived preadipocytes with the CB1 agonist, methanandamide,31 induced 
a higher time- and dose-dependent NO release in ischemics than in nonischemics, and this effect was 
specifically inhibited by the CB1 antagonist, AM251. Reciprocally, the CB2 agonist, JWH015, induced higher 
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NO production in nonischemics than in ischemics, and this effect was specifically inhibited by the CB2 
antagonist, AM630. 
The signalling data in preadipocytes supported this scenario, since ischemics displayed predominant 
activation of the PKA pathway and iNOS induced via CB1 activation, whereas nonischemics displayed 
predominant activation of the PLC/PKC pathway and eNOS induced via CB2 stimulation. In line with these 
findings, the CB1-mediated production of NO in ischemics was specifically inhibited by PKA inhibitors, 
whereas that mediated by CB2 in nonischemics was specifically inhibited by PKC inhibitors. A potential 
cAMP/PKA and PLC/PKC pathway in CB receptor-coupled signal transduction is not a new 
finding.2 Moreover, these data confirm previous observations obtained in human adipocytes and 
preadipocytes3 and those related to CB1- and CB2-coupled Gs or Gi/o protein function modulation.32 Hence, 
while CB1 was reported to modulate adenylyl cyclase activity and the cAMP/PKA pathway through its 
ability to couple to both Gs and Gi/o proteins, CB2 was found to interact only with Gi/o protein, thus reducing 
the cAMP/PKA pathway.2 
The shift of the iNOS-to-eNOS ratio toward iNOS may be relevant for ischemics, since iNOS produces the 
highest NO amounts and has been involved in several pathologic conditions.15 NO has been described as a 
biological “double-edged sword,” playing roles in cellular protection but also in cytotoxicity.33 In particular, 
low levels of NO were shown to reversibly inhibit mitochondrial transition pore opening, whereas high 
levels could be involved in oxido-nitrosative tissue damage34 and would cause apoptosis.35 
The results obtained in preadipocytes are in line with observations on the different roles played by CB1 and 
CB2 in several systems. On one hand, CB1 activation in endothelial cells and cardiomyocytes is shown to 
amplify the reactive oxygen species–MAPK-dependent cell death pathway in inflammatory conditions and 
oxidative and nitrosative stress.36 and 37 On the other hand, the stimulation of CB2 has been found to 
protect the kidney against cisplatin-induced injury, to contribute to infarct size–limiting effects mediated by 
anandamide, and to limit atherosclerotic plaque progression by attenuating the inflammatory 
response.33, 38, 39 and 40 Moreover, the activation of CB2 was found to be involved in cardiac protection 
against ischemia and reperfusion injuries through the restoration of iNOS-to-eNOS equilibrium.15 ERK1/2 is 
a member of the so-called reperfusion injury salvage kinase pathway, which is essential for 
cardioprotection against ischemic injuries.41 Thus, the fact that ERK1/2 activation was higher in 
nonischemics than in ischemics would indicate a cell death–prone status in the latter. Furthermore, recent 
findings have shown that endocannabinoids could exert a strong cardioprotective effect mainly through 
CB2 with the involvement of p38, ERK1/2, and PKC activation.14 In addition, this study shows for the first 
time that changes in CB receptor expression can be observed in ischemic cardiac disease in EAT and human 
myocardium.7 
Conclusions 
At present, one cannot rule out the causal relationship between myocardial ischemia and the EAT CB1 bias, 
however recent findings showing that FAAH activity suppresses the myocardial cell death induced by 
endocannabinoid, which was partly mediated by CB1 stimulation.42 supports the idea that the setting of the 
ECS in EAT may indeed play a role in the myocardial damage in ischemics. Furthermore, and although not 
clearly demonstrated, the shift of CB1/CB2 ratio toward CB1 in ischemics could be related to changes in 
local vascularization affecting biochemical, metabolic pattern and receptors expression of EAT, involving 
the ECS, as well. 
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Our ischemic heart-disease patients differed from the patients without ischemic heart disease in 2 
significant ways: (1) a much higher prevalence of prior myocardial infarction (MI) and (2) much more 
history of heart failure. The results of the present study do not allow us to determine whether the 
differences in the ECS might have contributed to the risk of MI or heart failure, whether prior MI or heart 
failure contributed to the endocannabinoid changes, or whether there is no causal relationship. Further 
work is needed to address the potential pathophysiological role of the ECS in epicardial fat on myocardial 
function and ischemia, and of myocardial ischemia and failure on the epicardial fat ECS. 
In summary, our results suggest a different role played by the ECS in EAT in the presence or absence of 
ischemic heart disease. In cases of ischemia, CB1 receptor and PKA upregulation, accompanied by CB2 
receptor and FAAH downregulation, lead to an increased iNOS-to-eNOS ratio and reduction of cell survival 
signalling. In nonischemic conditions, the CB2 receptor-related pathway is involved in cardioprotection 
through iNOS-to-eNOS ratio restoration and the involvement of PLC/PKC and ERK1/2 signalling. 
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